Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TRANSCODE THERAPEUTICS INC (RNAZ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.60+1.91%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RNAZ yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital allocation including acquisitions and equity financing | A primary condition in TRANSCODE THERAPEUTICS INC's published investment case. The stated target is Complete $14 million equity financing and sustain capital through 2026-Q1. | Intact | Failure to secure planned equity financing or capital runs out in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, not a proven compounder: the company is loss-making, recent financial performance is weak, and risk is high. The long-term thesis is in a watch state, with low confidence and volatile management execution.
Valuation evidence is thin, so whether RNAZ is cheap or expensive versus peers cannot be established. The evidence does not show what expectations are already reflected in valuation, and the company is loss-making.
Near term, earnings risk is elevated because the company has missed across recent quarters, and the supplied estimate puts next-quarter miss probability at 85%. In the multi-year view, RNAZ reports Phase 2a development of TTX-MC138 and a patient-identification collaboration, but operating income was negative in 2026-Q2 and revenue is not reported in the supplied financials.
The thesis hinges on progress in TTX-MC138 and whether the announced review of the oncology portfolio produces a demonstrated outcome; no transaction is reported in the supplied materials. Near-term sector support could continue if bellwethers VRTX, REGN, and MRNA keep beating and guiding higher, while weaker employment data or weaker bellwether results could erode that tailwind.
Over the next 1 to 3 years, RNAZ remains a high-risk, low-confidence story with clinical progress but weak financial evidence and unresolved strategic execution. The thesis depends on clinical development and concrete outcomes from the portfolio review. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance clinical development of lead candidate TTX-MC138 | TransCode is advancing its lead drug TTX-MC138 in trials. | Improving | No progress or delays in Phase 1a or Phase 2a trials in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “These findings support advancing TTX-MC138 into Phase 2a clinical development to assess efficacy in patients with circulating tumor DNA (ctDNA) positive colorectal cancer following curative-intent therapy.” “The program is being evaluated in a Phase 2a trial in patients with circulating tumor DNA (ctDNA)-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative under its PRE-I-SPY program.” Net income was $-6.750 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Address Nasdaq listing compliance and regulatory challenges | A supporting condition in TRANSCODE THERAPEUTICS INC's published investment case. The stated target is Resolve Nasdaq deficiency notices and maintain listing through 2026. | Intact | Company is delisted from Nasdaq or fails to meet listing rules in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.72 → $-6.72 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-25 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-26 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-27 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-28 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-29 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-30 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-07-31 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-01 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-02 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-03 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-04 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-05 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-06 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-08 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-09 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-10 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-12 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-13 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-14 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-15 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-16 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-17 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-18 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-19 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-20 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-21 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-22 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-23 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-24 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-25 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-26 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-27 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-28 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-29 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-30 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-08-31 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-01 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-02 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-03 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-04 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-05 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-06 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-07 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-08 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-09 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-10 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-11 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-12 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-13 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-14 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-15 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-16 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-17 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-18 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-19 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-20 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-21 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-22 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-23 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-24 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-25 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-26 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-27 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-28 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-29 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-09-30 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-01 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-02 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-03 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-04 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-05 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-06 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-07 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-08 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-09 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-10 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-11 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-12 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-13 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-14 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-15 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-16 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-17 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-18 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-19 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-20 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-21 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-22 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-23 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-24 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-25 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-26 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-27 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-28 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-29 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-30 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-10-31 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-11-01 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-11-02 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-11-03 | $-6.72 | $9,700,000 | 1 / 1 |
| 2026-11-04 | $-6.72 | $9,700,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.